ASAHI INTECC CO., LTD. announces a Chronic Total Occlusion (CTO) indication for its Corsair, Corsair Pro Microcatheters and its Coronary Guide Wires to include MIRACLEbros series, CONFIANZA series, FIELDER series and Gaia series. This marks a significant milestone as it is the first expanded indication for ASAHI devices in the United States. CTO’s are common findings in patients with coronary artery disease. A CTO is defined as complete occlusion of a coronary vessel for at least 3 months. CTO’s in major coronary arteries continue to present significant obstacles to complete percutaneous revascularization and are a common reason for patients to be...

Two real-world analyses featuring the Medtronic plc AdaptivCRT(TM) algorithm reinforce that its use is linked to a reduction in atrial fibrillation (AF) episodes, as well as tied to higher patient activity levels. The results, involving 408 patients with heart failure and a Medtronic cardiac resynchronization therapy (CRT) device at 26 centers in Italy, were unveiled at the European Heart Rhythm Association (EHRA) Scientific Sessions 2018 in Barcelona, Spain. The first analysis revealed a significant reduction in the incidence of AF episodes of all measured durations (greater than...

In 2017, Medtronic, C. R. Bard, and Philips raked in approximately $300 million in revenue from the U.S. drug-coated balloon (DCB) market. Launched in the United States in late 2014, DCBs have quickly secured an important place in the endovascular specialist’s arsenal for treating lower-limb peripheral arterial disease (PAD) and, more recently, dysfunctional dialysis fistulae. However, recent reimbursement changes, new product launches, and broadening indications for established platforms leave the future of the DCB market uncertain. The Transitional Pass-Through Payment Expires The Centers for Medicare and Medicaid Services (CMS) transitional pass-through (TPT) payment temporarily provides...

CorMedix Inc., a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced that it is in negotiations with its contract research organization (“CRO”) regarding certain remediation efforts and financial considerations for the ongoing delay incurred by the Company in performing the interim efficacy analysis of the LOCK-IT-100 study. The Company is currently anticipating that the Data Safety Monitoring Board (“DSMB”) will...